PMC:7463108 / 24953-25277 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T197","span":{"begin":209,"end":218},"obj":"Body_part"}],"attributes":[{"id":"A197","pred":"fma_id","subj":"T197","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"Neuroinflammation; morphine tolerance (antinociception), physical withdrawal, reward Tat1–86 No Morphine (75 mg pellet, 5 days) • ↑ Tolerance (↓ anti-nociceptive potency and ↓ withdrawal symptoms)\n• ↑ CPP and cytokines (24 h after withdrawal)\n• Above effects reduced by CCR5 blockade Mouse, Tat tg, males (Gonek et al. 2018)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T68","span":{"begin":0,"end":17},"obj":"Disease"}],"attributes":[{"id":"A68","pred":"mondo_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/MONDO_0004466"}],"text":"Neuroinflammation; morphine tolerance (antinociception), physical withdrawal, reward Tat1–86 No Morphine (75 mg pellet, 5 days) • ↑ Tolerance (↓ anti-nociceptive potency and ↓ withdrawal symptoms)\n• ↑ CPP and cytokines (24 h after withdrawal)\n• Above effects reduced by CCR5 blockade Mouse, Tat tg, males (Gonek et al. 2018)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T240","span":{"begin":284,"end":289},"obj":"http://purl.obolibrary.org/obo/CLO_0007836"},{"id":"T241","span":{"begin":299,"end":304},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T242","span":{"begin":299,"end":304},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T243","span":{"begin":319,"end":323},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"}],"text":"Neuroinflammation; morphine tolerance (antinociception), physical withdrawal, reward Tat1–86 No Morphine (75 mg pellet, 5 days) • ↑ Tolerance (↓ anti-nociceptive potency and ↓ withdrawal symptoms)\n• ↑ CPP and cytokines (24 h after withdrawal)\n• Above effects reduced by CCR5 blockade Mouse, Tat tg, males (Gonek et al. 2018)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T183","span":{"begin":19,"end":27},"obj":"Chemical"},{"id":"T185","span":{"begin":96,"end":104},"obj":"Chemical"},{"id":"T186","span":{"begin":201,"end":204},"obj":"Chemical"}],"attributes":[{"id":"A183","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_17303"},{"id":"A184","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_58097"},{"id":"A185","pred":"chebi_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/CHEBI_17303"},{"id":"A186","pred":"chebi_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/CHEBI_34603"}],"text":"Neuroinflammation; morphine tolerance (antinociception), physical withdrawal, reward Tat1–86 No Morphine (75 mg pellet, 5 days) • ↑ Tolerance (↓ anti-nociceptive potency and ↓ withdrawal symptoms)\n• ↑ CPP and cytokines (24 h after withdrawal)\n• Above effects reduced by CCR5 blockade Mouse, Tat tg, males (Gonek et al. 2018)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"586","span":{"begin":85,"end":89},"obj":"Gene"},{"id":"587","span":{"begin":270,"end":274},"obj":"Gene"},{"id":"588","span":{"begin":291,"end":294},"obj":"Gene"},{"id":"662","span":{"begin":284,"end":289},"obj":"Species"}],"attributes":[{"id":"A586","pred":"tao:has_database_id","subj":"586","obj":"Gene:72472"},{"id":"A587","pred":"tao:has_database_id","subj":"587","obj":"Gene:12774"},{"id":"A588","pred":"tao:has_database_id","subj":"588","obj":"Gene:234724"},{"id":"A662","pred":"tao:has_database_id","subj":"662","obj":"Tax:10090"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Neuroinflammation; morphine tolerance (antinociception), physical withdrawal, reward Tat1–86 No Morphine (75 mg pellet, 5 days) • ↑ Tolerance (↓ anti-nociceptive potency and ↓ withdrawal symptoms)\n• ↑ CPP and cytokines (24 h after withdrawal)\n• Above effects reduced by CCR5 blockade Mouse, Tat tg, males (Gonek et al. 2018)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T378","span":{"begin":0,"end":196},"obj":"Sentence"},{"id":"T379","span":{"begin":197,"end":242},"obj":"Sentence"},{"id":"T380","span":{"begin":243,"end":318},"obj":"Sentence"},{"id":"T381","span":{"begin":319,"end":324},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Neuroinflammation; morphine tolerance (antinociception), physical withdrawal, reward Tat1–86 No Morphine (75 mg pellet, 5 days) • ↑ Tolerance (↓ anti-nociceptive potency and ↓ withdrawal symptoms)\n• ↑ CPP and cytokines (24 h after withdrawal)\n• Above effects reduced by CCR5 blockade Mouse, Tat tg, males (Gonek et al. 2018)"}